Repare Therapeutics (NASDAQ:RPTX) Price Target Lowered to $4.00 at Stifel Nicolaus

Repare Therapeutics (NASDAQ:RPTX) had its price target dropped by stock analysts at Stifel Nicolaus from $9.00 to $4.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 0.76% from the company’s previous close.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a research note on Friday, November 8th.

Repare Therapeutics Price Performance

Shares of RPTX opened at $3.97 on Friday. The firm has a 50-day simple moving average of $3.34 and a two-hundred day simple moving average of $3.36. Repare Therapeutics has a 1-year low of $2.71 and a 1-year high of $8.49. The stock has a market cap of $168.76 million, a PE ratio of -1.99 and a beta of 0.71.

Institutional Trading of Repare Therapeutics

A number of large investors have recently modified their holdings of RPTX. Barclays PLC grew its stake in Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after purchasing an additional 7,800 shares in the last quarter. Stifel Financial Corp grew its position in shares of Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after buying an additional 13,800 shares in the last quarter. Vontobel Holding Ltd. increased its stake in shares of Repare Therapeutics by 20.0% during the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after buying an additional 4,000 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Repare Therapeutics by 21.2% during the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after buying an additional 8,809 shares during the period. Finally, Blue Owl Capital Holdings LP raised its holdings in Repare Therapeutics by 8.0% in the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after acquiring an additional 250,000 shares in the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.